Immediate Impact
1 hit
Citing Papers
Claudin 18.2 as a novel therapeutic target
2024 Hit
Works of Xiangdong Qu being referenced
Safety results of Q-1802, a Claudin18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors in a phase 1 study.
2022